Published: 2022-11-23

Disease profile of Guillain-Barré syndrome among Indian patients receiving intravenous immunoglobulin: a real-world observational study

Anil Rajani, Lav Patel, Shreekant Sharma


Background: Objectives of the study were to evaluate the real-world usage pattern of intravenous immunoglobulin (IVIg) for the treatment of patients with Guillain‐Barré syndrome (GBS), and to understand the disease characteristics and demographic patterns of these patients.

Methods: This real-world, retrospective, analysis included data of patients with GBS who received IVIg treatment at various centers across India. The study data was collected between April 2021 and March 2022.  

Results: A total of 3064 patients with GBS who received IVIg treatment were included. The mean (SD) age of the patients was 48.97 (14.97) years, and majority of the patients were men (68.8%). Acute inflammatory demyelinating polyneuropathy (AIDP) was the most common subtype of GBS (60.5%), followed by acute motor axonal neuropathy (AMAN; 11.6%), and acute motor sensory axonal neuropathy (AMSAN; 3%). The majority (>94%) of patients received IVIg therapy as first-line treatment. A large proportion of the patients (n=2402, 78.4%) were given the standard dose of 2 g/kg bodyweight (given over 5 days) and 97.1% (n=2974) of the total study population received IVIg regimen over the standard protocol of 5 days.

Conclusions: In the clinical spectrum of GBS, AIDP was the most common subtype. IVIg was used at generally recommended dose and duration in patients with GBS.


IVIg, Intravenous immunoglobulin, GBS, Guillain‐Barré syndrome

Full Text:



Nguyen TP, Taylor RS. Guillain Barre Syndrome. [Updated 2022 Jul 4]. In: StatPearls. Treasure Island (FL): StatPearls Publishing. 2022.

Van den Berg B, Walgaard C, Drenthen J, Fokke C, Jacobs BC, van Doorn PA. Guillain–Barré syndrome: pathogenesis, diagnosis, treatment and prognosis. Nat Rev Neurol. 2014;10:469-82.

Van Doorn PA, Kuitwaard K, Walgaard C, van Koningsveld R, Ruts L, Jacobs BC. IVIG treatment and prognosis in Guillain-Barré syndrome. J Clin Immunol. 2010;30(1):S74-8.

Hughes RA, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2014;Cd002063.

Benedetti L, Briani C, Beronio A, Massa F, Giorli E, Sani C, et al. Increased incidence of axonal Guillain-Barré syndrome in La Spezia area of Italy: A 13-year follow-up study. J Peripher Nerv Syst. 2019;24:80-6.

Piccione EA, Salame K, Katirji B. Guillain-Barré Syndrome and Related Disorders, in Neuromuscular Disorders in Clinical Practice. Katirji B, Kaminski HJ, Ruff RL. Springer New York: New York, NY. 2014;573-603.

Meena AK, Khadilkar SV, Murthy JM. Treatment guidelines for Guillain-Barré Syndrome. Ann Indian Acad Neurol. 2011;14:S73-81.

Leonhard SE, Mandarakas MR, Gondim FAA, Bateman K, Ferreira MLB, Cornblath DR, et al. Diagnosis and management of Guillain-Barré syndrome in ten steps. Nat Rev Neurol. 2019;15:671-83.

Shang P, Feng J, Wu W, Zhang H-L. Intensive Care and Treatment of Severe Guillain–Barré Syndrome. Front Pharmacol. 2021;12.

Rath J, Zulehner G, Schober B, Grisold A, Krenn M, Cetin H, et al. Real-world treatment of adult patients with Guillain-Barré syndrome over the last two decades. Scientif Rep. 2021;11:19170.

Dhadke SV, Dhadke VN, Bangar SS, Korade MB. Clinical profile of Guillain Barre syndrome. J Assoc Physicians India. 2013;61:168-72.

Rath J, Zulehner G, Schober B, Grisold A, Krenn M, Cetin H, et al. Real-world treatment of adult patients with Guillain-Barré syndrome over the last two decades. Sci Rep. 2021;11:19170.

Koga M, Yuki N, Hirata K. Antecedent symptoms in Guillain-Barré syndrome: an important indicator for clinical and serological subgroups. Acta Neurol Scand. 2001;103:278-87.

Sriwastava S, Kataria S, Tandon M, Patel J, Patel R, Jowkar A, et al. Guillain Barré Syndrome and its variants as a manifestation of COVID-19: A systematic review of case reports and case series. J Neurol Sci. 2021;420:117263.

Kalita J, Misra UK, Goyal G, Das M. Guillain-Barré syndrome: subtypes and predictors of outcome from India. J Peripher Nerv Syst. 2014;19:36-43.